Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2043)	12/6/2007 4:51:01 PM
From: Jibacoa	Respond to of 3722

ENZ shrs were up 16.42% during the regular session, although they aren't doing too well AHs.<g> The stock was clobbered on Sep 7 when it announced that the U.S. District Court for the District of Connecticut dismissed a patent lawsuit against Applied Biosystems that Enzo had in conjunction with Yale University. But today the stock is trading again above the $12 level & seems ready to test the Oct 17 H at 13.35 <g> bigcharts.marketwatch.com The patents at issue were based on the work of Dr. David C. Ward at Yale University. According to ENZ, those patents had been recognized by the scientific and biotechnology communities for more than 20 Yrs. as groundbreaking achievements in the field of nucleic acid. ENZ's President,Barry Weiner, noted that although they were planning on appealing the ruling,it related only to three expired patents, & it was unrelated to ENZ's ongoing operating business & it didn't impact ENZ's intellectual portfolio of more than 200 patents. ENZ has had 2 consecutive Qs of double digit improvements on revenues & has been trimming its losses.The short position was around 15x its AvgDV. The insider reportedly hold > 15% & institutions > 20% with the float around 30.5M It seems that ENZ should be able to close its Sep DG & be able to retest the $18 level, which would be a good % gain from present levels.<g> bigcharts.marketwatch.com Bernard